Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2005-03-30
2010-06-15
Helms, Larry R (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S001610, C435S339000
Reexamination Certificate
active
07736848
ABSTRACT:
Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
REFERENCES:
patent: 6033902 (2000-03-01), Haseltine et al.
patent: 6420338 (2002-07-01), Schneider et al.
patent: 2 362 952 (2001-12-01), None
patent: WO 00/17386 (2000-03-01), None
patent: WO 01/92562 (2001-12-01), None
Shiloh, Feb. 2001,Current Opinion in Genetics and Development, vol. 11, p. 71-77.
Asaad, N.A., et al., “Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization inXRCC2andXRCC3mutants,”Oncogene, 2000, 19, 5788-5800.
Blasina, A., et al., “Caffeine inhibits the checkpoint kinase ATM,”Curr. Biol., 1999, 9, 1135-1138.
Bohm, L., et al., “Inhibition of DNA repair by pentoxifylline and related methylxanthine derivatives,”Toxicology, 2003, 193(1-2), 153-160 (abstract 1 page).
Boyd, K.E., et al., “Coexamination of site-specific transcription factor binding and promoter activity in living cells,”Mol. &Cell. Biol., 1999, 19(12), 8393-8399.
Brin, E., et al., “Modeling the late steps in HIV-1 retroviral integrase-catalyzed DNA integration,”J. of Biol. Chem., 2000, 275(50), 39287-39295.
Cliby, W.A., et al., “Overexpresion of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints,”EMBO J., 1998, 17(1), 159-169.
Cliby, W.A., et al., “S phase and G2arrests induced by topoisomerase I poisons are dependent on ATR kinase function,”J. Biol. Chem., 2002, 277(2), 1599-1606.
Coffin, J.M., et al.,Retroviruses, Cold Spring Harbor Laboratory, 1997, Abstract 3 pages.
Cortez, D., et al., “Requirement of ATM-dependent phosphorylation of Brca 1 in the DNA damage response to double-strand breaks,”Science, 1999, 286, 1162-1166.
Cortez, D., et al., “ATR and ATRIP: partners in checkpoint signaling,”Science, 2001, 294, 1713-1716.
Daniel, R., et al., “A role for DNA-PK in retroviral DNA integration,”Science, 1999, 284, 644-647.
Daniel, R., et al., “Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses,”Mol. &Cell Biol., 2001, 21(4), 1164-1172.
Daniel, R., “Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response,”PNAS, 2003, 100(8), 4778-4783.
de Klein, A., et al., “Targeted disruption of the cell-cycle checkpoint geneATRleads to early embryonic lethality in mice,”Curr. Biol., 2000, 10, 479-482.
Durocher, D., et al., “DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?,”Curr. Opin. +Cell Biol., 2001, 13, 225-231.
Franchitto, A., et al., “Bloom's syndrome protein is required for correct relocalization of RAD50/MRE11/NBS1 complex after replication fork arrest,”J. Cell Biol., 2002, 157(1), 19-30.
Gaken, J.A., et al., “Efficient retroviral infection of mammalian cells is blocked by inhibition of poly(ADP-ribose) polymerase activity,”J. of Virology, 1996, 70(6), 3992-4000.
Hall-Jackson, CA., et al., “ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK,”Oncogene, 1999, 18, 6707-6713.
Katz, R.A., et al., “The retroviral enzymes,”Ann. Rev. Biochem., 1994, 63, 133-173.
Katz, R.A., et al., “Role of DNA end distortion in catalysis by avian sarcoma virus integrase,”J. Biol. Chem., 2001, 276(36), 34213-34220.
Lakin, N.D., et al., “The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53,”Oncogene, 1999, 18, 3989-3995.
Liu, Q., et al., “Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint,”Genes&Dev., 2000, 14, 1448-1459.
Naldini, L., et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,”Science, 1996, 272, 263-267.
Nunnari, G., et al., “Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections,”Aids, 2002, 16, 39-45.
Ohnishi, A., et al., “Differential pharmacokinetics of theophylline in elderly patients,”Drugs Aging, 2003, 20(1), 71-84.
Orlando, V., “Mapping chromosomal proteins in vivo, by formaldehyde-crosslinked-chromatin immunoprecipitation,”TIBS, 2000, 25, 99-104.
Otero, M., et al., “Peripheral blood dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART,”AIDS Res. &Hum. Retroviruses, 2003, 19(12), 1097-1103.
Patel, C.A., et al., “Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells,”J. Virol, 2000, 74(20), 9717-9726.
Patel, C.A., et al., “Lentiviral expression of HIV-1 Vpr induces apoptosis in human neurons,”J. Neurovirol, 2002, 8, 86-99.
Pleasure, S.J., et al., “NTera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell,”J. Neurosci. Res., 1993, 35, 585-602.
Pleasure, S.J., et al., “Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons,”J. Neurosci, 1992, 12(5), 1802-1815.
Pommier, Y., et al., “Inhibitors of human immunodeficiency virus integrase,” Adv. In VirusRes., 1999, 52, 427-458.
Post, S., et al., “Phosphorylation of serines 635 and 645 of human Rad17 in cell cycle regulated and is required for G1/S checkpoint activation in response to DNA damage,”Proc. Natl. Acad. Sci. USA, 2001, 98(23), 13102-13107.
Sarkaria, J.N., et al., “Inhibition of ATM and ATR kinase activities by the radiosensitizing,”Cancer Res., 1999, 59, 4375-4382.
Sarkaria, J.N., et al., “ATM as a target for novel radiosensitizers,”Semin. Radiat. Oncol., 2001, 11(4), 316-327.
Shiloh, Y., “ATM and ATR: networking cellular responses to DNA damage,”Curr. Opin. In Genet. &Devel., 2001, 11,71-77.
Takase, K., et al., “Reversible G1arrest induced by dimethyl sulfoxide in human lymphoid cell lines: kinetics of the arrest and expression of the cell cycle marker proliferating cell nuclear antigen in Raji cells,”Cell Growth&Differ, 1992, 3, 515-521.
Take, Y., et al., “OK-1035, a selective inhibitor of DNA-dependent protein kinase,”Biochem. &Biophys. Res. Comm., 1995, 215(1), 41-47.
Tibbetts, R.S., et al., “A role for ATR in the DNA damage-induced phosphorylation of p53,”Genes&Dev., 1999, 13, 152-157.
Tibbetts, R.S., et al., “Functional interactions BRCA1 and the checkpoint kinase ATR during genotoxic stress,”Genes&Dev., 2000, 14, 2989-3002.
Wang, T.G., et al., “In vitro cellular tropism of human T cell leukemia virus type 2,”AIDS Res. &Hum. Retroviruses, 2000, 16(16), 1661-1668.
Ward, I.M., et al., “Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress,”J. Of Biol. Chem., 2001, 276(51), 47759-47762.
Yoder, K.E., et al., “Repair of gaps in retroviral DNA integration intermediates,”J. of Virol., 2000, 74(23), 11191-11200.
Zhou, B.-B. S., et al., “Caffeine abolishes the mammalian G2/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity,”J. Biol. of Chem., 2000, 275(14), 10342-10348.
Zho
Daniel Rene
Kao Gary D.
Nunnari Giuseppe
Pomerantz Roger J.
Skalka Anna Marie
Boesen Agnieszka
Drinker Biddle & Reath LLP
Fox Chase Cancer Center
Helms Larry R
LandOfFree
Cellular targets for treatment of retroviral infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cellular targets for treatment of retroviral infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cellular targets for treatment of retroviral infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189965